Alpha Tau treats first patient in U.S. multi-center pancreatic cancer trial

Alpha Tau (DRTS) Medical announced that the first patient has been treated in its U.S. multi-center pancreatic cancer pilot study, known as IMPACT, evaluating the safety, feasibility, and efficacy of Alpha DaRT in combination with chemotherapy for patients with newly diagnosed unresectable locally advanced or metastatic pancreatic adenocarcinoma. Uzi Sofer, CEO of Alpha Tau, stated, “With the vast majority of pancreatic cancer patients deemed inoperable at diagnosis, the need for innovation is urgent. The initiation of the IMPACT trial in the U.S. marks an important step by exploring how Alpha DaRT, with its ultra-high dose and localized alpha radiation, might complement chemotherapy in treating this terrible disease. This pilot study is a key part of our broader strategy to bring Alpha DaRT to cancer patients with some of the highest unmet needs.”